Halozyme issues 2023 revenue, adj. EPS guidance below estimates, shares fall ~7%
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
46,035€
6,56%
Echtzeit-Aktienkurs Halozyme Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Halozyme Therapeutics Inc. Aktie
Halo Therapeutics stock drops following weak 2023 outlook
Halozyme Therapeutics Inc. HALO stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall…
Halozyme Provides 2023 Financial Guidance and Outlook
2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from…
Form 8-K HALOZYME THERAPEUTICS, For: Jan 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Zacks.com featured highlights Halozyme Therapeutics, Arista Networks and Citizens Financial Group
Halozyme Therapeutics, Arista Networks and Citizens Financial Group have been highlighted in this Screen of The Week article....…
3 Stocks to Keep an Eye on for Earnings Growth in 2023
As 2023 approaches, its prudent to have a look at stocks like Halozyme Therapeutics (HALO), Arista Networks (ANET) & Citizens…
Halozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technology
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Epinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technavio
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Epinephrine autoinjector market insights - Vendors: 15+, including Adamis Pharmaceuticals Corp., ALK Abello…
Halozyme initiated Overweight at Wells Fargo on partnerships, patent moat
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
4 Analysts Have This to Say About Halozyme Therapeutics
Latest Ratings for HALO
DateFirmActionFromTo Nov 2021Wells FargoMaintainsOverweight Nov 2021JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkMaintainsOutperform
…
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do…
Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings?
Halozyme Therapeutics (HALO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings…